Potential Factors Influencing Regional Differences and Similarities in Multiregional Clinical Trials

被引:0
作者
Masahiko Ohishi
机构
[1] MSD,Department of Biostatistics & Research Decision Sciences, Japan Development
来源
Drug information journal : DIJ / Drug Information Association | 2012年 / 46卷
关键词
multiregional clinical trials; regional differences; potential factors of regional differences;
D O I
暂无
中图分类号
学科分类号
摘要
In a multiregional clinical trial (MRCT), determining whether regional differences occur by chance or whether they are due to differences in pharmacokinetics, pharmacodynamics, or other prognostic factors is important to accurately evaluate the true efficacy of a drug in patients of each region. The general probability that regional results will differ from total results has been studied using statistical simulation. Consideration from the pharmacokinetic perspective is necessary as well to investigate the causes of regional differences. Patient characteristics may vary among regions, and differences in medical environment such as commonly used drugs and treatment guidelines can affect regional efficacy and safety results. Moreover, bias may be introduced in the data collected due to differences such as in diagnosis, assessment criteria, and reporting conditions. In this research, the factors and mechanism potentially influencing results by region in MRCT are examined, referring to the results of MRCTs already published.
引用
收藏
页码:565 / 572
页数:7
相关论文
共 20 条
[1]  
Hjalmarson A(1999)Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) Lancet 353 2001-2007
[2]  
Goldstein S(2000)Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure JAMA 283 1295-1302
[3]  
Fagerberg B(2001)Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial Am Heart J 142 502-511
[4]  
Wedel H(2005)Multicentre trials: a US regulatory perspective Stat Methods Med Res 14 303-318
[5]  
DeMets D(2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-869
[6]  
Deedwania P(2003)Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial Br J Urol Int 92 741-747
[7]  
Anello C(2010)Regional differences in multinational clinical trials: anticipating chance variation Clin Trials 7 147-156
[8]  
O’Neill RT(1995)Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19 Clin Pharmacokinet 29 45-52
[9]  
Dubey S(1999)International Society of Hypertension guidelines for the management of Hypertension J Hypertens 17 151-183
[10]  
Brenner BM(2007)An approach to rationalize partitioning sample size into individual regions in a multiregional trial Drug Information Journal 42 139-147